MICROBA

Microba to Present at International Microbiome Conference

Microba Life Sciences Limited (ASX: MAP) ("Microba" or the "Company") is pleased to announce Global Business Development lead, Mark Parker, will present at the 3rd International World of Microbiome Conference in Vienna on Saturday 30 April from 10:20AM CET (6:20PM AEST). Microba is continuing to attract new business opportunities in Europe through an increased presence following the COVID period. A copy of the presentation is attached to this announcement.

This announcement has been authorised for release by the Chairman and Chief Executive Officer.

For further information, please contact:

Dr Luke Reid Chief Executive Officer E: Luke.Reid@microba.com Simon Hinsley Investor / Media Relations E: simon@nwrcommunications.com.au T: +61 401 809 653

About Microba Life Sciences Limited

Microba Life Sciences is a precision microbiome company driven to improve human health. With world-leading technology for measuring the human gut microbiome, Microba is driving the discovery and development of novel therapeutics for major chronic diseases and delivering gut microbiome testing services globally to researchers, clinicians, and consumers. Through partnerships with leading organisations, Microba is powering the discovery of new relationships between the microbiome, health and disease for the development of new health solutions.

For more information visit: www.microba.com

Microba encourages all current investors to go paperless by registering their details with the designated registry service provider, Automic Group.


MICROBA

Microba's Discovery Platform A unique dataset for discovery

World of Microbiome | Vienna Mark Parker Global Business Development, Microba Life Sciences

April 2022 | Authorised for release by the CEO and Chairman


There is unequivocal evidence demonstrating the **human gut microbiome acts systemically** and is a critical factor in disease



Deficient analysis and fragmented datasets are limiting progress


- **Incomplete measurement** of gut microbiome communities
- High error rates with existing tools
- Underpowered datasets leading to unclear results
- **Resistance to culture** impedes efforts to assess therapeutic efficacy of priority microbes

Microba's data-driven discovery interrogates the novel microbiome




Precision techniques developed by Microba enable access to greater depth and breath of the microbiome with precision and efficiency.

Microba's leading metagenomics analysis platform measures the microbiome with **unparalleled performance**






In a real faecal sample, our analysis shows how much can be missed without precise metagenomic analysis




MICROBA Data generated by Microba Life Sciences

Using precision microbiome analysis to generate a **globally unique dataset** to power microbiome discovery




Human first, data-driven approach to microbiome discovery & development




Inflammatory Bowel Disease Program


Demonstrating rapid translation from data to first in human



Leads show strong *in vitro* **therapeutic activity** of cell migration and immune suppression - further elucidating mechanism of action




Advanced artificial intelligence and machine learning capabilities can discover strong signals from **complex datasets**



MICROBA Data generated by Microba Life Sciences

Identifying microbiome leads using a big data approach and multiple methods



Opportunities for partnership

to drive new discovery

Analysis Platform

End-to-end solution for precise and comprehensive microbiome analysis

- Clinical trial support
- End-to-end research services, including sample collection, bioinformatics and statistical analysis, and results interpretation

Discovery Platform

A globally unique data resource and advanced capabilities in data mining and AI

- Identify microbial biomarkers associated with health, disease, environment and lifestyle
- Discover microbiome directed interventions and probiotic leads

Therapeutic Platform

Human first, data-driven lead identification and proprietary isolation methods

 Develop novel microbiome derived drugs, including live microbial drugs and bioactive molecules

Access world-leading technology and expertise in microbiome analysis at any stage of your research.

Contact



Mark Parker Global Business Development Mark.parker@microba.com

Head Office

Level 10, 324 Queen Street, Brisbane, QLD Australia

Laboratory

Princess Alexandra Hospital, Brisbane, QLD Australia

Acknowledgements



Co-Founder, Non-Executive Director



Prof Phil Hugenholtz Co-Founder, Chair of Scientific Advisory Board



Dr Alena Pribyl

VP Drug Discovery



Dr Nicola Angel Laboratory Director Advisor, Strategic Alliances





Dr Kylie Ellis Head of Research Partnerships

Prof Ian Frazer Director and Chair Medical Advisory Board



14









Tim Lamberton



Charlotte Vivian Research Associate

Dr Andrea Rabellino

Senior Scientist Cell Biology



Scientist Microbiology

Dr Annika Krueger Scientist Cell Biology

Dr Donovan Parks Bioinformatic Consultant



A/Prof Jake Begun Medical Advisory Board, IBD Advisory Panel

Prof Maria Abreu IBD Advisory Board



Assoc Prof Paul Griffin Medical Advisory Board



Dr Martha Cooper

Data Scientist



Dr Joel Boyd

Bioinformatics Senior Scientist and Research Officer Researcher



Dr Michael Nissen Computational Immunologist



Alexander Hasson Scientist AI and Data-Mining

Mark Parker Global Business

Development

Dr Areej Alshiekh Bioinformatician

Dr David Wood







